Becker's Healthcare March 21, 2024
Less than two weeks after Novo Nordisk’s weight loss drug Wegovy was approved to reduce the risk of heart attacks and strokes, CMS has issued guidance for Medicare coverage of weight loss drugs, The Wall Street Journal reported March 21.
Per the guidance, Medicare Part D drug benefit plans may cover anti-obesity medications if they are approved for additional health benefits and used for those conditions, the agency told the news outlet. Medicare’s prescription drug benefit currently excludes weight loss medications when solely used for weight loss. The agency said it notified health plans on March 20 regarding the new guidance.
Many Part D plans already cover glucagon-like peptide-1 agonists such as Ozempic and Mounjaro for Type 2 diabetes....
Today's Sponsors
Today's Sponsor